PixarBio Corporation announced the expansion of NeuroRelease Pain Platform to include a 7-Day post-surgical pain treatment and a 3-Day sterile powder known as “Sprinkle-On” NeuroRelease. With recent patent application filings to the USPTO for “Sprinkle On” NeuroRelease, a sterile powder form to be sprinkled into incisions and wounds, both 7-Day and “Sprinkle-On” products are now covered in the PixarBio USPTO patent applications portfolio. NeuroRelease is a morphine strength, non-addictive pain treatment for the hospital setting, for the battlefield, or for acute and chronic pain. First product FDA approval for the platform will be for a 14-day post-surgical pain treatment is expected in 2018. A major benefit of NeuroRelease is there is no effect on locomotion nerve fibers, so patients can still control their locomotion nerve fibers movements and move around with a morphine strength treatment that is non-addictive. NeuroRelease only effects sensory or pain signaling nerve fibers. Like Vancomycin, an antibiotic that is sprinkled into incisions and wounds to reduce infection, NeuroRelease can be sprinkled into incisions and wounds to provide pain treatment. Since, NeuroRelease does not affect locomotion fibers, soldiers can move themselves to safety. Emergency room trauma is a logical application in the clinic and “Sprinkle On” NeuroRelease will be a welcomed new pain treatment option for physicians performing surgery. PixarBio NeuroRelease pain platform also includes 4-8 hour, 3-day, 7-day, 14-day and 90-Day pain treatments all have expected FDA approvals in 2020. NeuroRelease is biodegradable, and it’s non-toxic so NeuroRelease is the only non-opiate under review at the FDA that can be re-injected to extend treatment timelines.